Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heterogeneous nuclear ribonucleoprotein A1-like 3 (HNRNPA1L3) appears to refer to either an uncharacterized gene, a pseudogene, or an alternative name for a non-coding element related to the heterogeneous nuclear ribonucleoprotein (hnRNP) A1 family. In available scientific literature and databases, HNRNPA1L3 lacks direct evidence for being an established protein-coding gene or a validated molecular target. Aliases such as "HNRNPA1P48" suggest it may be a pseudogene (a non-coding DNA sequence similar to a known gene but typically lacking protein-coding function). There are many characterized members of the hnRNP family (such as hnRNP A1, A2/B1, etc.) that participate in RNA binding, splicing, and gene regulation[1][2][3], but HNRNPA1L3 is not among those with clearly documented biological function, molecular activity, or disease associations. No evidence exists for druggability, functional or clinical relevance, or utility as a biomarker.\n\n**Key Notes:**\n- Most likely a pseudogene or a non-coding genomic element.\n- Not recognized as a receptor, enzyme, transporter, or typical drug target.\n- No specific biological functions or disease processes directly attributed to HNRNPA1L3.\n- No drugs, mechanisms of action, biomarkers, or safety concerns reported.\n- The term is likely *incorrect* as a therapeutic target without further experimental validation or clarification.\n\nIf your query relates to **hnRNP A1** (not "A1-like 3"), refer to the parent protein, a well-studied RNA-binding protein involved in splicing, mRNA transport, telomere regulation, and tumor cell metabolism[1][2][3][4]. However, HNRNPA1L3 itself does not appear in major gene, protein, or drug resources as a functional, actionable molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein A1-like 3 (HNRNPA1L3).